Explanipedia

Phenotypic heterogeneity and plasticity in colorectal cancer metastasis Open

Samuel Ogden, Nasrine Metic, Ozen Leylek, Elise Smith, Alison Berner , et al. · 2025

Author Correction: Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells Open

Marta Buzzetti, Sonia Morlando, Dimitrios Solomos, Ammara Mehmood, Alexander W. I. Cox , et al. · 2025

Genetic and immune landscape evolution in <span>MMR‐</span> deficient colorectal cancer Open

Benjamin Challoner, Andrew Woolston, David K. Lau, Marta Buzzetti, Caroline Fong , et al. · 2023

Mismatch repair‐deficient (MMRd) colorectal cancers (CRCs) have high mutation burdens, which make these tumours immunogenic and many respond to immune checkpoint inhibitors. The MMRd hypermutator phenotype may also promote intratumour hete…

Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer Open

Benjamin Challoner, Andrew Woolston, David K. Lau, Marta Buzzetti, Caroline Fong , et al. · 2022

Mismatch repair deficient colorectal cancers have high mutation loads and many respond to immune checkpoint-inhibitors. We investigated how genetic and immune landscapes co-evolve in these tumors. All cases had high truncal mutation loads.…

Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells Open

Marta Buzzetti, Sonia Morlando, Dimitrios Solomos, Ammara Mehmood, Alexander W. I. Cox , et al. · 2021

Medulloblastoma (MB) is the most common aggressive paediatric brain tumour and, despite the recent progress in the treatments of MB patients, there is still an urgent need of complementary or alternative therapeutic options for MB infants.…

Differential Role of Circulating microRNAs to Track Progression and Pre-Symptomatic Stage of Chronic Heart Failure: A Pilot Study Open

Yuri D’Alessandra, Mattia Chiesa, Maria Cristina Carena, Antonio Paolo Beltrami, Paola Rizzo , et al. · 2020

(1)Background: Chronic heart failure (CHF) contributes to the overall burden of cardiovascular disease. Early identification of at-risk individuals may facilitate the targeting of precision therapies. Plasma microRNAs are promising circula…

Vulnerability of drug‐resistant EML4‐ALK rearranged lung cancer to transcriptional inhibition Open

Athanasios R. Paliouras, Marta Buzzetti, Lei Shi, Ian J. Donaldson, Peter Magee , et al. · 2020

Mechanisms of medulloblastoma vulnerability and new targeted therapies Open

Marta Buzzetti · 2020

Medulloblastoma (MB) is the most common malignant paediatric brain tumour accounting for about 20% of all childhood brain cancers. Over the last decade, a consensus has been reached over the existence of 4 main molecular subtypes, known as…

A Specific Circulating MicroRNA Cluster Is Associated to Late Differential Cardiac Response to Doxorubicin-Induced Cardiotoxicity <i>In Vivo</i> Open

Clarissa Ruggeri, Sonia Gioffré, Mattia Chiesa, Marta Buzzetti, Giuseppina Milano , et al. · 2018

Background . Cardiotoxicity is a detrimental side effect of the anticancer drug doxorubicin (DOX), characterized by progressive heart dysfunction. Circulating microRNAs (miRNAs) are recognized as potential biomarkers of cardiac disease; th…

Plasmatic and chamber-specific modulation of cardiac microRNAs in an acute model of DOX-induced cardiotoxicity Open

Sonia Gioffré, Veronica Ricci, Chiara Vavassori, Clarissa Ruggeri, Mattia Chiesa , et al. · 2018

miRNAs in bone metastasis Open

Douglas G. Cheung, Marta Buzzetti, Gianpiero Di Leva · 2017

Bone metastasis is one of the most common forms of metastasis from a number of different primary carcinomas. MicroRNAs (miRNAs) are short, endogenous RNAs that negatively regulate gene expression to control essential pathways, including th…

P3986Circulating microRNAs correlate with heart failure presence and progression Open

Yuri D’Alessandra, Marta Buzzetti, Clarissa Ruggeri, Antonio Paolo Beltrami, Maria Cristina Carena , et al. · 2017

Heart failure -Diagnostic assessment 829 those without any of them (59% vs 33% vs 13%, respectively, p<0.0001).Hazard ratio (HR) for cardiac death of abnormal 6MWT and greater ADMIRE-HF risk score (7.3 [95% CI 2.6 to 20.7]) was 2.5-fold of…

Marta Buzzetti YOU? Author Swipe